Besides, propagermanium (a CCR2 inhibitor) and maraviroc (a CCR5 inhibitor) are also considered as relative chemotactic axis inhibitors, which all promote the amelioration of NASH in murine models (121, 122). This evidence concerns the gene CCR2 and metabolic dysfunction-associated steatohepatitis.